CRMD News and Press, CorMedix Inc. From 03/28/22

CorMedix (NASDAQ:CRMD) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.23 (-21.1% Y/Y) and the consensus Revenue Estimate is $0.01M (-83.3% Y/Y). For further details see: CorMedix Q4 2021 Earnings Preview

AMPE, AREC, CALM, CHWY, CRMD, CWBR, CWCO, HTGM, INFI, OTCQB:LQMT, LULU, MLKN, MOTS, MU, MVST, NBRV, NBY, OTC:OIBZQ, OPGN, PAVM, PRGS, PVH, RH, SNDL, SPWH, SUNL, VRNT, ZVO For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesd...

5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10. For further details see: Citius: 2022 Is A Year Of Catalysts

CorMedix (NASDAQ:CRMD) is trading ~7% higher in the pre-market Monday after the development stage pharma company announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for DefenCath, an anti-infective solution. The regulators have determin...

BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the resubmission ...

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report it...

CorMedix (NASDAQ:CRMD) has appointed experienced pharmaceutical leader Joseph Todisco as CEO and a member of its Board of Directors. Mr. Todisco is expected to join CorMedix on May 16th or such earlier date as he completes his contractual responsibilities to his current employer. Previously, ...

BERKELEY HEIGHTS, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Jos...

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...